[
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential",
    "summary": "We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other Billionaire Ken Fisher’s healthcare stock picks with massive upside potential. The healthcare industry, an essential component of global […]",
    "url": "https://finnhub.io/api/news?id=1071ea0bd185b7ddf6028f382448947338712618640d597340ec685482f1ad7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745780883,
      "headline": "Merck & Co., Inc. (MRK): Among Billionaire Ken Fisher’s Healthcare Stock Picks with Massive Upside Potential",
      "id": 134115167,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other Billionaire Ken Fisher’s healthcare stock picks with massive upside potential. The healthcare industry, an essential component of global […]",
      "url": "https://finnhub.io/api/news?id=1071ea0bd185b7ddf6028f382448947338712618640d597340ec685482f1ad7b"
    }
  },
  {
    "ts": null,
    "headline": "KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma",
    "summary": "RAHWAY, N.J., April 27, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Results at the first interim analysis of the trial showed KEYTRUDA significantly improved event-free survival (EFS) as part",
    "url": "https://finnhub.io/api/news?id=3fc0f2253870e0d3e5273b62f624758e8a36b731368c21884fd80e16d801250f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745769600,
      "headline": "KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma",
      "id": 134107527,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., April 27, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Results at the first interim analysis of the trial showed KEYTRUDA significantly improved event-free survival (EFS) as part",
      "url": "https://finnhub.io/api/news?id=3fc0f2253870e0d3e5273b62f624758e8a36b731368c21884fd80e16d801250f"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks",
    "summary": "As tariffs loom over the sector, biotechs with U.S.-based manufacturing and intellectual property are soothing investor concerns.",
    "url": "https://finnhub.io/api/news?id=a7b86d481014d6d18633c5e47f4a166c1806e4c71992a1314cb2756118891ef1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745751600,
      "headline": "Wall Street’s New Tariff Safe Haven: High-Tax Biotech Stocks",
      "id": 134107528,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "As tariffs loom over the sector, biotechs with U.S.-based manufacturing and intellectual property are soothing investor concerns.",
      "url": "https://finnhub.io/api/news?id=a7b86d481014d6d18633c5e47f4a166c1806e4c71992a1314cb2756118891ef1"
    }
  },
  {
    "ts": null,
    "headline": "Immunocore Holdings: A Name On My Watch List",
    "summary": "Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find out why IMCR stock is a hold.",
    "url": "https://finnhub.io/api/news?id=3c6035336bf5c6df95c8c2c41f4bb7678f2cb4517ebf7bcec662837a6db9b49d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745745753,
      "headline": "Immunocore Holdings: A Name On My Watch List",
      "id": 134106725,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1473708731/image_1473708731.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find out why IMCR stock is a hold.",
      "url": "https://finnhub.io/api/news?id=3c6035336bf5c6df95c8c2c41f4bb7678f2cb4517ebf7bcec662837a6db9b49d"
    }
  }
]